Headpin Inhibitors
Headpin Inhibitors are a class of compounds that can directly or indirectly decrease the functional activity of Headpin. These inhibitors primarily act through inhibiting specific signaling pathways or cellular processes in which Headpin is directly involved. Staurosporine, a potent inhibitor of protein kinases including PKC, can lead to the decreased functional activity of Headpin, given Headpin is a downstream effector of PKC. Genistein, a tyrosine kinase inhibitor, can lead to the functional inhibition of Headpin and its activity is mediated by tyrosine phosphorylation.
Moreover, LY294002 and Wortmannin are PI3K inhibitors. PI3K signaling often leads to activation of PKC, and as Headpin is a downstream effector of PKC, inhibition of PI3K can result in decreased Headpin activity. Rapamycin, an mTOR inhibitor, can also lead to decreased Headpin activity, given that mTOR is an upstream regulator of PKC. Additionally, U0126, PD98059, Selumetinib, and Trametinib are MEK inhibitors. As MEK is involved in the ERK signaling pathway, and ERK can activate PKC, the inhibition of MEK can indirectly lead to decreased Headpin activity. SB203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, can both lead to decreased Headpin activity since both p38 MAPK and JNK can activate PKC. Lastly, BAY 11-7082 is an NF-κB pathway inhibitor, and given that NF-κB can activate PKC, inhibition of this pathway can lead to decreased Headpin activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases including PKC. As Headpin is a downstream effector of PKC, the inhibition of PKC by Staurosporine can lead to decreased functional activity of Headpin. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. If Headpin's activity is mediated by tyrosine phosphorylation, Genistein can lead to the functional inhibition of Headpin by blocking this phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling often leads to activation of PKC, and as Headpin is a downstream effector of PKC, inhibition of PI3K can result in decreased Headpin activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Given that mTOR is an upstream regulator of PKC, which in turn activates Headpin, inhibition of mTOR can logically lead to decreased Headpin activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Given that p38 MAPK can activate PKC, which in turn activates Headpin, the inhibition of p38 MAPK can lead to decreased Headpin activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Since JNK can activate PKC, and PKC activates Headpin, the inhibition of JNK can lead to decreased Headpin activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. By inhibiting MEK, which can activate PKC, it can potentially lead to decreased Headpin activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor. Inhibiting PI3K, which can activate PKC, can logically lead to decreased Headpin activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an NF-κB pathway inhibitor. Given that NF-κB can activate PKC, and PKC is an activator of Headpin, inhibition of the NF-κB pathway can lead to decreased Headpin activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor. By inhibiting MEK, which can activate PKC, it can potentially lead to decreased Headpin activity. | ||||||